Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024
Adicet Bio (NASDAQ: ACET) has announced its upcoming participation at the American College of Rheumatology (ACR) Convergence 2024 meeting in Washington, D.C., scheduled for November 14-19, 2024. The company will deliver an oral presentation about ADI-001, their allogeneic CD20-targeted γδ CAR T cell therapy, which shows potential for improved tissue homing in autoimmune indications. The presentation, titled under abstract number 1866169, will be delivered by Dr. Monica Moreno on November 19, 2024, at 12:00 p.m. ET during the Miscellaneous Rheumatic & Inflammatory Diseases II session.
Adicet Bio (NASDAQ: ACET) ha annunciato la sua prossima partecipazione alla Convergenza 2024 del Collegio Americano di Reumatologia (ACR) che si terrà a Washington, D.C., dal 14 al 19 novembre 2024. L'azienda presenterà un intervento orale su ADI-001, la loro terapia cellulare CAR T allogenica mirata al CD20, che mostra potenziale per un miglioramento nella migrazione tissutale nelle indicazioni autoimmuni. La presentazione, intitolata con il numero di astrazione 1866169, sarà tenuta dalla Dr.ssa Monica Moreno il 19 novembre 2024, alle 12:00 ET, durante la sessione Malattie Reumatiche e Infiammatorie Varie II.
Adicet Bio (NASDAQ: ACET) ha anunciado su próxima participación en la Convergencia 2024 del Colegio Americano de Reumatología (ACR) que se llevará a cabo en Washington, D.C., del 14 al 19 de noviembre de 2024. La compañía realizará una presentación oral sobre ADI-001, su terapia de células T CAR γδ dirigida al CD20, que muestra potencial para mejorar la migración tisular en indicaciones autoinmunes. La presentación, titulada con el número de resumen 1866169, será realizada por la Dra. Monica Moreno el 19 de noviembre de 2024, a las 12:00 p.m. ET durante la sesión de Enfermedades Reumáticas e Inflamatorias II.
Adicet Bio (NASDAQ: ACET)는 2024년 11월 14일부터 19일까지 워싱턴 D.C.에서 열리는 미국 류마티즘학회(ACR) 컨버전스 2024에 참가할 것이라고 발표했습니다. 이 회사는 자가 면역 질환에서 조직 이주 개선 가능성을 보이는 ADI-001, CD20 표적의 동종 장기화 γδ CAR T 세포 치료에 대한 구두 발표를 진행할 예정입니다. 이 발표는 초록 번호 1866169로, 모니카 모레노 박사가 2024년 11월 19일 오후 12시(동부 표준시)에 다양한 류마티스 및 염증성 질환 II 세션에서 진행할 예정입니다.
Adicet Bio (NASDAQ: ACET) a annoncé sa prochaine participation à la Convergence 2024 du Collège Américain de Rhumatologie (ACR) qui se tiendra à Washington, D.C., du 14 au 19 novembre 2024. La société fera une présentation orale sur ADI-001, leur thérapie CAR T γδ ciblant le CD20, qui montre un potentiel d'amélioration de l'homogénéité tissulaire dans les indications auto-immunes. La présentation, intitulée sous le numéro de résumé 1866169, sera faite par Dr. Monica Moreno le 19 novembre 2024 à 12h00 ET lors de la session sur les Maladies Rhumatologiques et Inflammatoires Diverses II.
Adicet Bio (NASDAQ: ACET) hat seine bevorstehende Teilnahme an der American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C., die vom 14. bis 19. November 2024 stattfinden wird, bekannt gegeben. Das Unternehmen wird eine mündliche Präsentation über ADI-001 halten, ihre allogenetische CD20-zielgerichtete γδ CAR T-Zelltherapie, die Potenzial für eine verbesserte Gewebeansiedlung bei Autoimmunerkrankungen zeigt. Die Präsentation mit der Abstract-Nummer 1866169 wird von Dr. Monica Moreno am 19. November 2024 um 12:00 Uhr ET während der Sitzung zu Verschiedenen Rheumatologischen und Entzündlichen Erkrankungen II gehalten.
- None.
- None.
Details of the oral presentation are as follows:
Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Session Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II
Abstract Number: 1866169
Presenting Author: Monica Moreno, Ph.D.
Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105685914/en/
Adicet Bio., Inc.
Investor and Media Contacts
Investors:
Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com
Media:
Kerry Beth Daly
kbdaly@adicetbio.com
Source: Adicet Bio, Inc.
FAQ
When will Adicet Bio (ACET) present at ACR Convergence 2024?
What therapy will Adicet Bio (ACET) present at ACR Convergence 2024?
Who will present Adicet Bio's (ACET) research at ACR Convergence 2024?
What is the abstract number for Adicet Bio's (ACET) presentation at ACR 2024?
